The existing therapeutic agents for CNV are only medicines for symptomatic therapies, and therefore a radical therapeutic agent for CNV has been keenly demanded. There is no therapeutic agent for Dry AMD, and therefore a radical therapeutic agent for Dry AMD has been keenly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, which contains a compound having an activity of suppressing the epithelial mesenchymal transition of a retinal pigment epithelial cell as an active ingredient. The present invention also provides a drusen formation suppressor, which contains a compound having an activity of suppressing the epithelial mesenchymal transition of a retinal pigment epithelial cell as an active ingredient.CNV之治療藥僅存在藉由對症療法之醫藥，而強烈謀求用以根治之治療藥。另外，不存在乾性AMD之治療藥，而強烈謀求用以根治乾性AMD之治療藥。本發明提供一種脈絡膜新生血管之預防及/或治療劑，係含有具有視網膜色素上皮細胞之上皮間質轉化抑制活性之化合物作為有效成分。另外，本發明提供一種隱結抑制劑，係含有具有視網膜色素上皮細胞之上皮間質轉化抑制活性之化合物作為有效成分。
